TNS3 and familial pancreatic carcinoma: Therefore, the smart nanoplatform will be able to encapsulate anti-mitochondrial metabolism agent (CPI-613), contain a TPP passive mitochondrial targeting moiety, and release ROS-triggered drugs to improve drug delivery ability and therapeutic efficacy in pancreatic cancer cell lines.